Dr. Fadi Al Akhrass, MD

Dr. Al Akhrass practices at Pikeville Medical Center in Pikeville, Kentucky, part of Pikeville Hospital.

Dr. Al Akhrass' NPI, 1245557222, was assigned on April 29, 2010. Dr. Al Akhrass holds Kentucky license 43193.

Dr. Al Akhrass' primary practice is Pikeville Medical Center, at 911 Bypass Road, Pikeville, KY 41501 in Pike County. The practice phone is (606) 437-3500.

Dr. Al Akhrass' primary practice is Pikeville Medical Center in Pikeville, Kentucky, part of Pikeville Hospital. The medical group on file is Pikeville Medical Center. Dmand AI also links Dr. Al Akhrass to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Al Akhrass practices, 2 sites in all. Vendor and product names are available with a free account.

Infectious disease is Dr. Al Akhrass' primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. Al Akhrass is licensed in Kentucky.

CMS data shows 302 Medicare services from Dr. Al Akhrass across 6 procedure codes in 2024, for 146 Medicare patients. Medicare paid $17,926 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 146 Medicare patients who saw Dr. Al Akhrass in 2024. The largest group is 65 to 74, with 54 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 40% are also on Medicaid. Their average risk score is 2.79, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Al Akhrass' median patient age at 60, with 46% women.

In 2024, Dr. Al Akhrass wrote 1,084 Medicare Part D claims for 178 patients. 76% of them were for generic drugs. CMS names the drug for 892 of them, across 24 drugs with 11 or more claims each, at $737,257 in total drug cost. In 2023, CMS named 1,064 claims across 29 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Al Akhrass for performance year 2024, reported as part of a group. Dr. Al Akhrass accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

CMS Open Payments shows 777 general payments to Dr. Al Akhrass from 37 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 74% of the total. Gilead Sciences, Inc. paid the most, $186,391.